Eli Lilly: positive results for tirzepatide
(CercleFinance.com) - Eli Lilly announced this weekend that results from a Phase III study showed that tirzepatide 'significantly' reduced the risk of worsening heart failure-related events in adults with heart failure with preserved ejection fraction (HFpEF) and obesity.
Specifically, the drug reduced the risk of hospitalisation for heart failure by 56% and improved symptoms and physical limitations.
Treated patients also improved their exercise capacity, walking 38.2 metres more in six minutes, and reduced their body weight by 15.7%, compared with 2.2% for placebo.
The steering committee, said that these results offer significant perspectives for the management of patients with HFpEF and obesity.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Specifically, the drug reduced the risk of hospitalisation for heart failure by 56% and improved symptoms and physical limitations.
Treated patients also improved their exercise capacity, walking 38.2 metres more in six minutes, and reduced their body weight by 15.7%, compared with 2.2% for placebo.
The steering committee, said that these results offer significant perspectives for the management of patients with HFpEF and obesity.
Copyright (c) 2024 CercleFinance.com. All rights reserved.